Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

June 12, 2017
Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression

June 8, 2017
Sage Therapeutics to Present at Goldman Sachs Healthcare Conference

June 5, 2017
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read More News

Associated Team Members

Kevin Starr
Partner